Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes | Latest News RSS feed

Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes - Latest News


Farxiga cuts hospitalisation for heart failure or CV death, study shows

“The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of ... read more

Study shows AZ’s Farxiga diabetes drug cuts heart risks

Since then other diabetes drugs have also been shown to improve cardio outcomes, such as Novo Nordisk’s Victoza (liraglutide) in the LEADER study. AstraZeneca said in the phase III DECLARE-TIMI 58 tri... read more

Farxiga gets positive result in DECLARE-TIMI 58

"The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of ... read more

Looking for another news?


AstraZeneca's dapagliflozin reduced CV risk in large-scale T2D study

AstraZeneca (NYSE:AZN) announces positive results from a large-scale cardiovascular outcomes study, DECLARE-TIMI 58, evaluating Farxiga (dapagliflozin) in more than 17,000 adults with type 2 diabetes ... read more


AstraZeneca announces positive results from phase III DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga to treat type-2 diabetes

“The DECLARE-TIMI 58 results offer compelling evidence that dapagliflozin helps to address an important medical need among a diverse group of patients with type-2 diabetes by reducing the composite of ... read more

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

Presentations will include findings from some of the largest trials in broad patient populations with FARXIGA (dapagliflozin) in type 2 diabetes (T2D), BRILINTA (ticagrelor) in patients with a history ... read more

AZ says target of $45bn sales by 2023 still achievable

AZ’s CEO also highlighted diabetes therapy Farxiga (dapagliflozin ... DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association ( ... read more

AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

“SGLT-2i is associated with lower risk of mortality and heart failure ... Dapagliflozin (DAPA) Across the Phase 2b/3 Clinical Trial Program.” American Diabetes Association Scientific Sessions 2017. Ab... read more

CANVAS PROGRAM: A road-block in the SGLT-2 inhibitor juggernaut?

EMPA-REG Summary (2): This was the first cardiovascular outcomes trial which demonstrated a statistically significant reduction in cardiovascular death (38% relative risk reduction), hospitalisation d... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us